Trends in Pricing and Out-of-Pocket Spending on Entecavir among Commercially Insured Patients, 2014-2018

Jonathan D. Alpern; Heesoo Joo; Ben Link; Antonio Ciaccia; William M. Stauffer; Nathan C. Bahr; Thomas M. Leventhal

doi:10.1001/jamanetworkopen.2021.44521

Trends in Pricing and Out-of-Pocket Spending on Entecavir among Commercially Insured Patients, 2014-2018

Jonathan D. Alpern, Heesoo Joo, Ben Link, Antonio Ciaccia, William M. Stauffer, Nathan C. Bahr, Thomas M. Leventhal

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.

Original language	English (US)
Article number	e2144521
Journal	JAMA Network Open
Volume	5
Issue number	1
DOIs	https://doi.org/10.1001/jamanetworkopen.2021.44521
State	Published - Jan 21 2022

Bibliographical note

Funding Information:
Author Contributions: Drs Alpern and Joo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Alpern, Joo, Link, Stauffer, Bahr, Leventhal. Acquisition, analysis, or interpretation of data: Alpern, Joo, Link, Ciaccia, Stauffer, Leventhal. Drafting of the manuscript: Alpern, Joo, Leventhal. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Joo. Administrative, technical, or material support: Alpern, Link, Bahr. Supervision: Ciaccia, Stauffer, Leventhal. Conflict of Interest Disclosures: Dr Alpern reported receiving funding from Arnold Ventures during the drafting of the manuscript for an unrelated study. Mr Ciaccia reported having clients that include the American Pharmacists Association, Ohio Pharmacists Association, and American Pharmacy Cooperative Incorporated; he reported having performed previous work for Capital Rx, a transparent pharmaceutical manager that uses national average drug acquisition cost methodology for pricing pharmacy claims. Dr Stauffer reported receiving an honorarium from Fishawack Health/Emergent BioSolutions and royalties from UpToDate outside the submitted work. Dr Bahr reported receiving research funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (No. K23NS110470) for unrelated work. No other disclosures were reported.

Keywords

Antiviral Agents/economics
Deductibles and Coinsurance/trends
Fees and Charges/trends
Financing, Personal/trends
Guanine/analogs & derivatives
Health Expenditures/trends
Humans
United States

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

Publisher link

10.1001/jamanetworkopen.2021.44521

Find It

Find It at U of M Libraries

Cite this

@article{eb96141ca9f54fb39a27821ed0aae631,

title = "Trends in Pricing and Out-of-Pocket Spending on Entecavir among Commercially Insured Patients, 2014-2018",

abstract = "This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.",

keywords = "Antiviral Agents/economics, Deductibles and Coinsurance/trends, Fees and Charges/trends, Financing, Personal/trends, Guanine/analogs & derivatives, Health Expenditures/trends, Humans, United States",

author = "Alpern, {Jonathan D.} and Heesoo Joo and Ben Link and Antonio Ciaccia and Stauffer, {William M.} and Bahr, {Nathan C.} and Leventhal, {Thomas M.}",

note = "Funding Information: Author Contributions: Drs Alpern and Joo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Alpern, Joo, Link, Stauffer, Bahr, Leventhal. Acquisition, analysis, or interpretation of data: Alpern, Joo, Link, Ciaccia, Stauffer, Leventhal. Drafting of the manuscript: Alpern, Joo, Leventhal. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Joo. Administrative, technical, or material support: Alpern, Link, Bahr. Supervision: Ciaccia, Stauffer, Leventhal. Conflict of Interest Disclosures: Dr Alpern reported receiving funding from Arnold Ventures during the drafting of the manuscript for an unrelated study. Mr Ciaccia reported having clients that include the American Pharmacists Association, Ohio Pharmacists Association, and American Pharmacy Cooperative Incorporated; he reported having performed previous work for Capital Rx, a transparent pharmaceutical manager that uses national average drug acquisition cost methodology for pricing pharmacy claims. Dr Stauffer reported receiving an honorarium from Fishawack Health/Emergent BioSolutions and royalties from UpToDate outside the submitted work. Dr Bahr reported receiving research funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (No. K23NS110470) for unrelated work. No other disclosures were reported.",

year = "2022",

month = jan,

day = "21",

doi = "10.1001/jamanetworkopen.2021.44521",

language = "English (US)",

volume = "5",

journal = "JAMA Network Open",

issn = "2574-3805",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - Trends in Pricing and Out-of-Pocket Spending on Entecavir among Commercially Insured Patients, 2014-2018

AU - Alpern, Jonathan D.

AU - Joo, Heesoo

AU - Link, Ben

AU - Ciaccia, Antonio

AU - Stauffer, William M.

AU - Bahr, Nathan C.

AU - Leventhal, Thomas M.

N1 - Funding Information: Author Contributions: Drs Alpern and Joo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Alpern, Joo, Link, Stauffer, Bahr, Leventhal. Acquisition, analysis, or interpretation of data: Alpern, Joo, Link, Ciaccia, Stauffer, Leventhal. Drafting of the manuscript: Alpern, Joo, Leventhal. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Joo. Administrative, technical, or material support: Alpern, Link, Bahr. Supervision: Ciaccia, Stauffer, Leventhal. Conflict of Interest Disclosures: Dr Alpern reported receiving funding from Arnold Ventures during the drafting of the manuscript for an unrelated study. Mr Ciaccia reported having clients that include the American Pharmacists Association, Ohio Pharmacists Association, and American Pharmacy Cooperative Incorporated; he reported having performed previous work for Capital Rx, a transparent pharmaceutical manager that uses national average drug acquisition cost methodology for pricing pharmacy claims. Dr Stauffer reported receiving an honorarium from Fishawack Health/Emergent BioSolutions and royalties from UpToDate outside the submitted work. Dr Bahr reported receiving research funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (No. K23NS110470) for unrelated work. No other disclosures were reported.

PY - 2022/1/21

Y1 - 2022/1/21

N2 - This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.

AB - This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.

KW - Antiviral Agents/economics

KW - Deductibles and Coinsurance/trends

KW - Fees and Charges/trends

KW - Financing, Personal/trends

KW - Guanine/analogs & derivatives

KW - Health Expenditures/trends

KW - Humans

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85123655797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123655797&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2021.44521

DO - 10.1001/jamanetworkopen.2021.44521

M3 - Article

C2 - 35061044

AN - SCOPUS:85123655797

SN - 2574-3805

VL - 5

JO - JAMA Network Open

JF - JAMA Network Open

IS - 1

M1 - e2144521

ER -

Trends in Pricing and Out-of-Pocket Spending on Entecavir among Commercially Insured Patients, 2014-2018

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this